3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
244
Lung Neoplasms
77
Melanoma
57
Carcinoma, Renal Cell
44
Small Cell Lung Carcinoma
33
Colorectal Neoplasms
28
Squamous Cell Carcinoma of Head and Neck
24
Carcinoma, Transitional Cell
24
Neoplasms
23
Triple Negative Breast Neoplasms
22
Neoplasm Metastasis
21
Carcinoma, Hepatocellular
19
Ovarian Neoplasms
17
Mesothelioma
17
Pancreatic Neoplasms
15
Mesothelioma, Malignant
15
Stomach Neoplasms
13
Breast Neoplasms
13
Uterine Cervical Neoplasms
12
Urinary Bladder Neoplasms
10
Head and Neck Neoplasms
10
Carcinoma, Merkel Cell
10
Kidney Neoplasms
9
Adenocarcinoma of Lung
8
Esophageal Neoplasms
7
Endometrial Neoplasms
7
Lymphoma
6
Carcinoma, Squamous Cell
6
Brain Neoplasms
6
Prostatic Neoplasms
5
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
taletrectinib
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
Nivolumab
×
Thoracic
×
Clear all
NCT04564157
2026-05-05
NADIM-ADJUVANT
Fundación GECP
Phase 3
Active not recruiting
210 enrolled
NCT05583188
2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4
Terminated
5 enrolled